CP-675,206 In Patients With Advanced Melanoma
NCT00086489
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
118
Enrollment
INDUSTRY
Sponsor class
Conditions
Malignant Melanoma
Interventions
DRUG:
CP-675,206
DRUG:
CP-675,206
Sponsor
AstraZeneca